top of page

Cancer Immunotherapy

Accellvecs Inc. provides a novel cancer immunotherapy technology using the autologous tumor cell vector (SynVC).

What is "SynVC"?

1. SynVC is a regenerative medicine product in which a cancer patient's own tumor cells are encapsulated with a natural killer T (NKT) cell-activating compound, and then cell death is induced in the tumor cells. 

2. When SynVC is returned to a cancer patient's body, Both dendritic cells (DCs) and NKT cells in the body are activated

3. It is possible to start the tretment within just one week after receiving the patient's cells.

Accellvecs

5-59-5 Yoyogi, Shibuya-ku,

Tokyo 151-0053 Japan

©2023 Accellvecs.Inc

bottom of page